Market revenue in 2023 | USD 3,512.1 million |
Market revenue in 2030 | USD 5,284.5 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 57.18% in 2023. Horizon Databook has segmented the Asia Pacific inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific inflammatory bowel disease treatment market is estimated to grow at a lucrative rate over the forecast period. High unmet medical needs, increasing prevalence of target diseases, growing adoption of novel treatments, and rising patient awareness are some of the key factors contributing to the growth.
Moreover, the presence of nonprofit organizations that provide information & train healthcare professionals and support patients affected with ulcerative colitis & Crohn’s disease is anticipated to fuel the Inflammatory Bowel Disease (IBD) treatment market.
It has been observed that Ulcerative Colitis (UC) is more common than Crohn’s Disease (CD) in the Asia Pacific. According to a study published by NCBI, the prevalence of Crohn’s disease is more likely among men than women.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific inflammatory bowel disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account